Jeff Berman

We connect clinicians to postoperative patients through MyHealthPal™: an AI-based postoperative wound monitoring technology that assesses wound health status, patient medication adherence, and patient vital signs to predict wound healing outcomes.

Mass Medical Angels (MA2) was founded to answer the need for a dedicated life-science centric angel group in New England. The Boston area is a world-leading supercluster for medical innovation, but all early-stage companies in the field have tremendous difficulty with first round funding. Our goal is to provide money and mentoring to the life science community to achieve superior returns for our group, and more clinical innovation for the community. Our focus is on early stage life science companies looking to raise $250K to $3.0M. Depending on the amount of funding needed, we can fund all or a portion of the round, and will work closely with other angel groups or venture funds in the area to complete the round. We are looking for companies that are extremely capital efficient opportunities where our funds will lead to significant step-ups in valuation to avoid unfavorable future funding rounds.

As a bioengineering incubator company, our mission is to accelerate the integration of engineering and life sciences to develop innovative products that can improve human health. At Aquillius, we have a team of engineers, scientists, and operators that can assist in designing, manufacturing, testing, and marketing your products. This support allows us to provide you with a strategy-driven, synchronized process that enables effective implementation and development of your IP. Our focus is to streamline and accelerate product development towards commercialization, from startups to large companies in the telecommunication, government, space exploration, and diagnostic sectors of business. Our ISO 13485 certified partner Microtek, allows us the ability to manage and manufacture microelectronic medical devices.

We connect clinicians to postoperative patients through MyHealthPal™: an AI-based postoperative wound monitoring technology that assesses wound health status, patient medication adherence, and patient vital signs to predict wound healing outcomes.

Centered within the Boston Healthcare ecosystem, ValueCurve is a boutique consulting and early stage investment firm focused on helping industry disruptors in the Healthcare, Life Science and Consumer products industries. We have expertise in Healthcare Technology, Medical Devices, Bio Medical and Diagnostics. We work with companies and management teams that share a passion for growth and value creation. We have developed a Speed to Value Framework that brings the best capabilities and solutions to clients to Invest, Improve, and Grow their businesses. Our founders and network of partners come from executive roles at the Big 4, leading healthcare and life science companies and successful start-ups. Many have over 30 years of industry, technology, and operations experience and have served some of the leading companies within the Fortune 500. ValueCurve specializes in creating enterprise value by developing differentiated products and services, accelerating workflows with digital technologies, implementing new operating models to disrupt markets and industries. Our expertise: VENTURE CAPITAL INVESTING- Early seed to Mid-stage growth capital for industry disruptors and scalable business models NEW VENTURE JUMP START PACKAGES- Strategy & Capability Assessment & Activation framework for obtaining capital, creating differentiation, business scale, market positioning and launch DUE DILIGENCE- Independent evaluation of Digital ecosystems, Intellectual Property, business operations and value realization roadmaps DIGITAL TRANSFORMATION- Digital strategies and plans to leverage AI, cloud platforms for tech modernization, IT cost reductions, workflow acceleration and scale EXECUTIVE IN RESIDENCE- Seasoned executives to guide management teams from start up to growth of operation

As a non-profit, our mission is to assist early-stage start-ups and entrepreneurs in the generation of innovative research and education in the fields of biotechnology, medical therapeutics, life sciences and beyond. To accomplish this we: 1) provide our residents with fully equipped and staffed lab and office space built using modern design principles 2) assist with applications for government and private funding for research, development and generation of a viable business plan 3) provide a range of professional business services from IT, to legal to accounting 4) offer educational opportunities via our mentorship program, memberships to key trade organizations, seminars, access to courses and networking events 5) access to our Advisory Board with expertise ranging from science, to business and entrepreneurship 6) create a collaborative environment that stimulates creative interactions amongst industry, investors, government and academia 7) maintain collaboration with premier research and academic institutions. The facility is conveniently located close to the cross-section of Routes I-95 and I-495, walking distance from the Commuter Rail, and short driving distance from the hubs of Providence and Boston/Cambridge.

Mass Medical Angels (MA2) was founded to answer the need for a dedicated life-science centric angel group in New England. The Boston area is a world-leading supercluster for medical innovation, but all early-stage companies in the field have tremendous difficulty with first round funding. Our goal is to provide money and mentoring to the life science community to achieve superior returns for our group, and more clinical innovation for the community. Our focus is on early stage life science companies looking to raise $250K to $3.0M. Depending on the amount of funding needed, we can fund all or a portion of the round, and will work closely with other angel groups or venture funds in the area to complete the round. We are looking for companies that are extremely capital efficient opportunities where our funds will lead to significant step-ups in valuation to avoid unfavorable future funding rounds.